John C Krauss, MD

 John C. Krauss
Clinical Professor of Internal Medicine
Medical School
University of Michigan
Hematology/Oncology
1500 East Medical Center Dr
Ann Arbor, MI 48109
[email protected]
Available to mentor
John C Krauss, MD
John C. Krauss
Clinical Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    I am the medical director of the multidisciplinary colorectal clinic, and I actively lead therapeutic clinical trials at the University of Michigan. I work with the Southwest Oncology Group, the NSABP Foundation, and pharmaceutical sponsors to make promising clinical trials available for my patients. I am actively working on eliminating surgery for selected patients with rectal cancer. I am interested in improving communication with my patients so they can get the optimum care for complex conditions.

    Qualifications
    • Hematology/Oncology Fellow
      University of Michigan Medical School, Internal Medicine, Ann Arbor, United States
      1988 - 1992
      Other
    • Internal Medicine Resident
      University of Minnesota Medical School, Internal Medicine, Minneapolis, United States
      1985 - 1988
    • MD
      University of Michigan, Ann Arbor, Michigan, United States
      1981 - 1985

    Center Memberships
    • Center Member
      Rogel Cancer Center
    • Center Member
      AI and Digital Health Innovation

    Research Overview

    The major focus of my research is experimental therapeutics of cancer. I have enrolled patients in FDA registration trials of irinotecan, nab-paclitaxel, regorafenib, and I have been the site principal investigator on the FDA registration trials of entrectinib, and NTRK and ROS1 inhibitor, sotorasib, a KRASG12c inhibitor, and fruquintinib, a VEGF inhibitor. I was the site principal investigator on the organ preservation of rectal cancer trial, which demonstrated that giving combined modality chemotherapy radiation therapy prior to systemic treatment improves the complete response rate of the tumor, so fewer patients need to have an operation.

    Recent Publications

     See All Publications
    • Journal Article
      Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer
      Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo Gracian A, Liu Y, van Buuren N, Shao J, Dong M, Chen A, Tejani M, Hecht JR. ESMO Gastrointestinal Oncology, 2026 Jun 1; 12: DOI:10.1016/j.esmogo.2026.100324
    • Journal Article
      NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
      Morris VK, Ciombor KK, Xiao L, Ochieng JK, Marmonti E, Polite B, Weinberg BA, Krauss JC, Hays J, Mukherjee S, Aranha O, Iqbal S, Shields T, Benson AB, Kazmi S, Lieu C, Hochster H, Whisenant J, Haymaker C, Eng C. J Clin Oncol, 2026 Jan 7; JCO2500929 DOI:10.1200/JCO-25-00929
      PMID: PMC12782278
    • Journal Article
      PCR71 Quality of Life Impact of Adverse Events Associated With Systemic Therapies for Metastatic Colorectal Cancer Previously Treated With Standard Therapies and Biologics Across 13 Countries in Europe, North America, and Asia
      Paly V, Alfonso PG, Chong G, Yoshino T, Krauss J, Shergill A, Elliott J, Krotneva S, Proskorovsky I, Hernandez LG. Value in Health, 2024 Dec 26; 27 (12): s518 DOI:10.1016/j.jval.2024.10.3314
    • Journal Article
      Exploring Chemotherapy-Induced Peripheral Neuropathy Management Practice Patterns Among Oncology Clinicians
      Kanzawa-Lee G, Krauss JC, Knoerl R. Seminars in Oncology Nursing, 2024 Oct 1; 40 (5): DOI:10.1016/j.soncn.2024.151685
      PMID: 38937199
    • Journal Article
      Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial
      Williams H, Yuval JB, Verheij FS, Miranda J, Lin ST, Omer DM, Qin LX, Gollub MJ, Kim TH, Garcia-Aguilar J, Patil S, Kim JK, Thompson HM, Marco MR, Lee M, Paty PB, Weiser MR, Nash GM, Pappou E, Wei IH, Widmar M, Segal NH, Cercek A, Yaeger R, Smith JJ, Wu AJ, Saltz LB, Dunne RF, Temple L, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Guillem JG, Goodman KA. British Journal of Surgery, 2024 Sep 1; 111 (9): DOI:10.1093/bjs/znae246
      PMID: 39319400
    • Journal Article
      MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer
      Williams H, Omer DM, Thomson HM, Lin ST, Verheij FS, Miranda J, Yuval JB, Buckley J, Marco MR, Qin LX, Dombroski DA, Kedar R, Oto A, Korngold E, Veniero JC, Gandhi S, Krishnaraj A, Jagtiani M, Ohanian K, Vu D, Hope TA, Lee S, Wasnik AP, Madhuripan N, Gollub MJ, Garcia-Aguilar J, Patil S, Kim JK, Lee M, Dunne RF, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Paty PB, Weiser MR, Nash GM, Pappou E, Guillem JG, Temple L, Wei IH, Widmar M, Segal NH, Cercek A, Yaeger R, Smith JJ, Goodman KA, Wu AJ, Saltz LB. Radiology, 2024 Sep 1; 312 (3): DOI:10.1148/radiol.232748
      PMID: 39225603
    • Journal Article
      Home-based aerobic exercise feasibility in oxaliplatin-receiving newly-diagnosed cancer survivors
      Kanzawa-Lee GA, Larson JL, Resnicow K, Ploutz-Snyder R, Krauss JC, Smith EML. European Journal of Oncology Nursing, 2024 Aug 1; 71: DOI:10.1016/j.ejon.2024.102649
      PMID: 38954929
    • Journal Article
      Treatment Modalities for Locally Recurrent Rectal Cancer: A Review
      Regan S, Hendren S, Krauss J, Crysler O, Cuneo K. The Cancer Journal: The Journal of Principles & Practice of Oncology, 2024 May 1;

    Featured News & Stories

         Man in a blue pullover against the background of Michigan Stadium
    Health Lab

    Thriving after a rectal cancer diagnosis

    Kyle Kipke was diagnosed with rectal cancer and received chemotherapy and radiation as treatment at Michigan Medicine.
         family posing together
    Health Lab

    Doctors perform first liver transplant in Michigan for colon cancer

    Andrew Sweeney was diagnosed with stage 4 colorectal cancer at age 31 and underwent a liver transplant, chemotherapy and radiation treatment.
         Cancer Aware surrounded by a circle of multicolor ribbons
    Cancer Aware

    Cutting edge treatment for advanced colon cancer

    Andrew Sweeney, now 35, was aware of his risk for colorectal cancer – his mother had had been diagnosed with it when she was 41. When he was 31, a CT scan at University of Michigan Health’s University Hospital revealed that Sweeney had a mass in his colon and potential metastases in his liver and lymph nodes. A colonoscopy confirmed that he had stage 4 colorectal cancer. After 1.5 years of chemotherapy, his care team began discussing how they could remove the damaged parts of Sweeney’s liver. They developed a colorectal cancer liver transplant protocol from a deceased donor and Sweeney was the first patient to undergo a liver transplant in Michigan for colon cancer. After minor recurrences of tumors in his lung in 2024, which were treated by surgery and radiation, his scans have been clear.